Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The aim of this study was to report the long-term safety of secukinumab in pooled data from 28 cli...

Полное описание

Библиографические подробности
Главные авторы: Alice B. Gottlieb, Atul Deodhar, Iain B. Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, Charis C. Papavassilis, Piotr Jagiello, Philemon Papanastasiou, Philip J. Mease, Mark Lebwohl
Формат: Статья
Язык:English
Опубликовано: Medical Journals Sweden 2022-04-01
Серии:Acta Dermato-Venereologica
Предметы:
Ankylosing spondylitis
biologics
interleukin
psoriasis
psoriatic arthritis
safety
Online-ссылка:https://medicaljournalssweden.se/actadv/article/view/563

Internet

https://medicaljournalssweden.se/actadv/article/view/563

Схожие документы